Bone mineral density fall during aromatase inhibitor treatment may predict lower breast cancer recurrence.
bone mineral density
breast cancer
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
08 Jan 2024
08 Jan 2024
Historique:
revised:
26
11
2023
received:
30
08
2023
accepted:
10
12
2023
medline:
8
1
2024
pubmed:
8
1
2024
entrez:
8
1
2024
Statut:
aheadofprint
Résumé
Aromatase inhibitors (AIs) are associated with reduction in bone mineral density (BMD). The use of bone strengthening agents zoledronic acid and denosumab are associated with improved breast cancer outcomes for post-menopausal patients treated with AIs. This study investigates whether change in BMD with AI therapy is associated with breast cancer recurrence. A cohort of patients treated at a single institution diagnosed with hormone receptor-positive breast cancer with baseline BMD and subsequent BMD test while receiving adjuvant aromatase inhibitor therapy were studied. Demographic, treatment and outcome data was obtained. Simple and multiple linear regression analysis was performed to investigate predictors of annual percent BMD change at the LS and hip. Univariate and multivariate Cox proportional hazards modelling were undertaken to investigate predictors of breast cancer recurrence. 353 patients eligible patients were identified. In multivariate analysis of lumbar spine BMD change, the difference between those in quartile 1, which showed the greatest reduction in BMD, and quartile 3, with substantially less reduction, was significant (HR = 3.02, 95% CI 1.15-7.90 p = 0.025). Hip BMD reduction was also not significantly associated with breast cancer recurrence. The two quartiles with the least reduction in hip BMD showing a non-significant reduced risk of recurrence relative to the quartile with the greatest (p = 0.10). The findings suggest an association may exist between lumbar spine BMD change and breast cancer recurrence for patients treated with adjuvant AI. Further research is required to determine whether BMD change can be utilised as a biomarker.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Riggs BLKS, Melton LJ 3rd. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 2002;23:279-302.
Finkelstein JS, Brockwell SE, Mehta V, et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab. 2008;93:861-868. doi:10.1210/jc.2007-1876
Neer R, on behalf of the SWAN investigators. Bone loss across the menopausal transition. Ann N Y Acad Sci. 2010;1192:66-71.
Lonning PE, Geisler J, Krag LE, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol. 2005;23:5126-5137. doi:10.1200/jco.2005.07.097
Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol. 2008;26:1051-1057. doi:10.1200/jco.2007.11.0726
Coleman RE, Banks LM, Girgis SI, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol. 2007;8:119-127. doi:10.1016/s1470-2045(07)70003-7
Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol. 2006;24:3629-3635. doi:10.1200/jco.2005.05.4882
Hadji P, Ziller M, Kieback DG, et al. Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy. Ann Oncol. 2009;20:1203-1209. doi:10.1093/annonc/mdn762
Tewari KS, Java JJ, Gatcliffe TA, Bookman MA, Monk BJ. Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: an exploratory study of the gynecologic oncology group. Gynecol Oncol. 2014;133:439-445. doi:10.1016/j.ygyno.2014.03.013
Ryanne WR, Lindenberg PA, Slack R, Noone AM, Marshall JL, He AR. Evaluation of hypertension as a marker of bevacizumab efficacy. J Gastrointest Cancer. 2009;40:101-108. doi:10.1007/s12029-009-9104-9
Chen C, Sun P, Ye S, Weng HW, Dai QS. Hypertension as a predictive biomarker for efficacy of bevacizumab treatment in metastatic colorectal cancer: a meta-analysis. J BUON. 2014;19:917-924.
Liu H-b, Wu Y, Lv T-f, et al. Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS ONE. 2013;8:e55128. doi:10.1371/journal.pone.0055128
Cuzick J, Sestak I, Cella D, Fallowfield L. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol. 2008;9:1143-1148. doi:10.1016/s1470-2045(08)70259-6
Huober J, Cole BF, Rabaglio M, et al. Symptoms of endocrine treatment and outcome in the BIG 1-98 study. Breast Cancer Res Treat. 2014;143:159-169. doi:10.1007/s10549-013-2792-7
Fontein DBY, Seynaeve C, Hadji P, et al. Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis. J Clin Oncol. 2013;31:2257-2264. doi:10.1200/jco.2012.45.3068
Mortimer JE, Flatt SW, Parker BA, et al. Tamoxifen, hot flashes and recurrence in breast cancer. Breast Cancer Res Treat. 2008;108:421-426. doi:10.1007/s10549-007-9612-x
Stearns V, Chapman J-AW, Ma CX, et al. Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial. J Clin Oncol. 2015;33:265-271. doi:10.1200/jco.2014.57.6926
Mieog JS, Morden JP, Bliss JM, Coombes RC, van de Velde CJ. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. Lancet Oncol. 2012;13:420-432. doi:10.1016/s1470-2045(11)70328-x
Kim J, Han W, Moon HG, et al. Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer. Breast Cancer Res. 2012;14:R102. doi:10.1186/bcr3221
Ko KL, Shin IS, You JY, Jung S-Y, Ro J, Lee ES. Adjuvant tamoxifen-induced mammographic breast density reduction as a predictor for recurrence in estrogen receptor-positive premenopausal breast cancer patients. Breast Cancer Res Treat. 2013;142:559-567. doi:10.1007/s10549-013-2726-4
Li J, Humphreys K, Eriksson L, Edgren G, Czene K, Hall P. Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer. J Clin Oncol. 2013;31:2249-2256. doi:10.1200/jco.2012.44.5015
Nyante SJ, Sherman ME, Pfeiffer RM, et al. Prognostic significance of mammographic density change after initiation of tamoxifen for ER-positive breast cancer. J Natl Cancer Inst. 2015;107(3). doi:10.1093/jnci/dju425
Kim BK, Choi YH, Nguyen TL, Nam SJ, Lee JE, Hopper JL. Mammographic density and risk of breast cancer in Korean women. Eur J Cancer Prev. 2015;24:422-429. doi:10.1097/cej.0000000000000099
Zaman K, Thürlimann B, Huober J, et al. Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). Ann Oncol. 2012;23:1474-1481. doi:10.1093/annonc/mdr448
DeCensi A, Sun Z, Guerrieri-Gonzaga A, et al. Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences. Breast Cancer Res Treat. 2014;144:321-329. doi:10.1007/s10549-014-2849-2
Ahlborg HG, Johnell O, Turner CH, Rannevik G, Karlsson MK. Bone Loss and Bone Size after Menopause. New Engl J Med. 2003;349:327-334. doi:10.1056/NEJMoa022464
Berger C, Langsetmo L, Joseph L, et al. Change in bone mineral density as a function of age in women and men and association with the use of antiresorptive agents. Can Med Assoc J. 2008;178:1660-1668. doi:10.1503/cmaj.071416
Lloyd JT, Alley DE, Hochberg MC, et al. Changes in bone mineral density over time by body mass index in the health ABC study. Osteoporos Int. 2016;27:2109-2116. doi:10.1007/s00198-016-3506-x
Ward KD, Klesges RC. A meta-analysis of the effects of cigarette smoking on bone mineral density. Calcif Tissue Int. 2001;68:259-270.
van den Brandt PA. A possible dual effect of cigarette smoking on the risk of postmenopausal breast cancer. Eur J Epidemiol. 2017;32:683-690. doi:10.1007/s10654-017-0282-7
Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126:529-537. doi:10.1007/s10549-010-1132-4
Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer. 2013;108:1515-1524. doi:10.1038/bjc.2013.116
McCowan C, Shearer J, Donnan PT, et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer. 2008;99:1763-1768. doi:10.1038/sj.bjc.6604758
Hsieh KP, Chen LC, Cheung KL, Chang CS, Yang YH. Interruption and non-adherence to long-term adjuvant hormone therapy is associated with adverse survival outcome of breast cancer women-an Asian population-based study. PLoS ONE. 2014;9:e87027. doi:10.1371/journal.pone.0087027
Marques EA, Mota J, Carvalho J. Exercise effects on bone mineral density in older adults: a meta-analysis of randomized controlled trials. Age. 2012;34:1493-1515. doi:10.1007/s11357-011-9311-8
Kemmler W, Engelke K, Lauber D, Weineck J, Hensen J, Kalender WA. Exercise effects on fitness and bone mineral density in early postmenopausal women: 1-year EFOPS results. Med Sci Sports Exerc. 2002;34:2115-2123. doi:10.1249/01.mss.0000039290.17644.09
Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354:669-683. doi:10.1056/NEJMoa055218
Cooper L, Clifton-Bligh PB, Nery ML, et al. Vitamin D supplementation and bone mineral density in early postmenopausal women. Am J Clin Nutr. 2003;77:1324-1329.
Hamer J, Warner E. Lifestyle modifications for patients with breast cancer to improve prognosis and optimize overall health. Can Med Assoc J. 2017;189:E268-E274. doi:10.1503/cmaj.160464
Zeichner SB, Koru-Sengul T, Shah N, et al. Improved clinical outcomes associated with vitamin D supplementation during adjuvant chemotherapy in patients with HER2+ nonmetastatic breast cancer. Clin Breast Cancer. 2015;15:e1-e11. doi:10.1016/j.clbc.2014.08.001
Coleman R, de Boer R, Eidtmann H, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol. 2013;24:398-405. doi:10.1093/annonc/mds277
Coleman R, Cameron D, Dodwell D, et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol. 2014;15:997-1006. doi:10.1016/S1470-2045(14)70302-X
Gnant M, Pfeiler G, Dubsky P, et al. Abstract S2-02: the impact of adjuvant denosumab on disease-free survival: results from 3,425 postmenopausal patients of the ABCSG-18 trial. Cancer Res. 2016;76:S2-02-S02-02. doi:10.1158/1538-7445.sabcs15-s2-02
Howe TE, Shea B, Dawson LJ, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev. 2011;(7):CD000333. https://doi.org/10.1002/14651858.CD000333.pub2
Tahririan MA, Motififard M, Omidian A, Aghdam HA, Esmaeali A. Relationship between bone mineral density and serum vitamin D with low energy hip and distal radius fractures: a case-control study. Arch Bone Joint Surg. 2017;5:22-27.
Fernandez-Valdivia R, Mukherjee A, Ying Y, et al. The RANKL signaling axis is sufficient to elicit ductal side-branching and alveologenesis in the mammary gland of the virgin mouse. Dev Biol. 2009;328:127-139. doi:10.1016/j.ydbio.2009.01.019
Schramek D, Penninger JM. The many roles of RANKL-RANK signaling in bone, breast and cancer. IBMS BoneKey. 2011;8:237-256.